Skip to main content
    P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $12.59
    -0.01 (-0.08%)

    Market Cap: $891.80M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Pharming Group NV (PHAR) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Pharming Group NV are Pharvaris BV (PHVS), Nuvectis Pharma (NVCT) and Theravance Biopharma (TBPH). Pharming Group NV trades at 39.3x earnings, against a median of 14.2x for the 3 of these companies with a P/E. By market cap, Pharming Group NV ranks 7th of the 13 companies on this page; Pharvaris BV (PHVS) is the largest at $2.36B.

    Peer Comparison

    PHAR's ROIC of 7.9% is above the peer median of -16.4%, and its revenue growth of 20.8% is above the median of 4.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Pharming Group NV (PHAR)$891.80M39.3x2.4x6.3%7.9%20.8%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Theravance Biopharma Inc (TBPH)$884.18M95.1x8.4x51.6%N/A-20.9%0.00%
    Phathom Pharmaceuticals Inc (PHAT)$492.63MN/A1.8x-30.2%11.4%71.1%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Uniqure NV (QURE)$1.67BN/A75.8x0.0%-57.9%40.4%0.00%
    CureVac NV (CVAC)$1.05BN/A1.8x182.1%N/A-89.0%0.00%
    Valneva SE ADR (VALN)$538.42MN/A3.2x-110.3%-44.2%-27.7%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Zevra Therapeutics Inc. (ZVRA)$540.30M11.6x3.7x52.8%N/A44.9%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    Peer median$917.01M14.2x3.5x0.0%-16.4%4.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Pharming Group NV, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Theravance Biopharma Inc (TBPH)
    Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and markets organ-selective drugs in the United States, Europe...
    Phathom Pharmaceuticals Inc (PHAT)
    Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
    PHAT competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Uniqure NV (QURE)
    uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases.
    QURE competitors
    CureVac NV (CVAC)
    CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA).
    Valneva SE ADR (VALN)
    Valneva SE, a company specialized in vaccines, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet...
    VALN competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors
    Zevra Therapeutics Inc. (ZVRA)
    Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions...
    ZVRA competitors
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors

    Frequently Asked Questions About PHAR

    Who are Pharming Group NV's main competitors?

    The companies most similar to Pharming Group NV include Pharvaris BV (PHVS), Nuvectis Pharma (NVCT), Theravance Biopharma (TBPH), Phathom Pharmaceuticals (PHAT) and Ultragenyx (RARE), listed from the closest match.

    Who is Pharming Group NV's biggest competitor?

    Pharvaris BV (PHVS) is both the largest of the similar companies at $2.36B and the closest match by business profile, size, sector and industry.

    How does PHAR stock compare with its competitors?

    PHAR's P/E is 39.3x against a peer median of 14.2x; its P/S is 2.4x against a peer median of 3.5x; its net margin is 6.3% against a peer median of 0.0%.

    Which of Pharming Group NV's competitors pays a higher dividend?

    Pharming Group NV pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Pharming Group NV bigger than its competitors?

    No. Pharming Group NV is 7th by market cap among the 13 companies on this page; the largest is Pharvaris BV (PHVS) at $2.36B.